Is Procter & Gamble (PG) overvalued or fairly valued?

MarketChacha shows Procter & Gamble's valuation in context — a trailing P/E of about 23.1, a forward P/E of about 21.6, a price-to-book of about 6.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Procter & Gamble's reported profit turn into cash?

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.20×) from reported figures — education, not a rating.

What is Procter & Gamble's revenue?

Procter & Gamble reported revenue of $87.0B for FY2026, with net profit of $16.0B, per official filings.

What is the share price of Procter & Gamble (PG)?

Procter & Gamble last traded at $159.35 (+1.4% on the day), as of 10/16/2026 — a delayed quote shown for education, not investment advice.

Procter & Gamble

PG · NYSE · Consumer Staples · United States

Snapshot

TickerPG

ExchangeNYSE

SectorConsumer Staples

IndustryHousehold & Personal Products

CountryUnited States

Employees104,000

HeadquartersCincinnati, United States

Websitewww.pginvestor.com

Filings tracked25

About Procter & Gamble

The Procter & Gamble Company provides branded consumer packaged goods worldwide. It operates through five segments: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The company offers conditioners, shampoos, styling aids, and treatments under the Head & Shoulders, Herbal Essences, Pantene, and Rejoice brands; antiperspirants, deodorants, and personal cleansing products under the Native, Old Spice, Safeguard, and Secret brands; and facial moisturizers, cleaners, and treatments under the Olay and SK-II brands. It also provides blades, razors, shave products, appliances, and other grooming products under the Braun, Gillette, and Venus brands. In addition, the company offers toothbrushes, toothpastes, and other oral care products under the Crest and Oral-B brands; and gastrointestinal, pain relief, rapid diagnostics, respiratory, vitamins/minerals/supplements, and other personal health care products under the Metamucil, Neurobion, Pepto-Bismol, and Vicks brands. Further, it provides fabric enhancers, and laundry additives and detergents under the Ariel, Downy, Gain, and Tide brands; and air and dish care, P&G professional, and surface care under the Cascade, Dawn, Fairy, Febreze, Mr. Clean, and Swiffer brands. Additionally, the company offers baby wipes, taped diapers, and pants under the Luvs and Pampers brands; adult incontinence and menstrual care products under the Always, Always Discreet, and Tampax brands; and paper towels, tissues, and toilet papers under the Bounty, Charmin, and Puffs brands. It sells its products through mass merchandisers, social ecommerce channels, grocery and specialty beauty stores, membership club stores, drug and department stores, distributors, wholesalers, airport duty-free and high-frequency stores, pharmacies, electronics stores, and professional channels, as well as directly to consumers. The company was founded in 1837 and is headquartered in Cincinnati, Ohio.

Who owns it

Insiders0.1%
Institutions71.8%
Public & other28.1%

5,007 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.18%
Vanguard Capital Management LLC6.55%
State Street Corporation4.40%
Geode Capital Management, LLC2.86%
Vanguard Portfolio Management LLC2.73%
Morgan Stanley2.03%
Charles Schwab Investment Management, Inc.2.03%
NORGES BANK1.37%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.20×

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend17.9% → 18.4%

Margin has held broadly steady over the period — stable profitability.

Return on equity29.5%

Latest ROE of 29.5% — capital is generating a healthy return.

Growth qualityrev 2% · PAT 3%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $22.7B · EPS 1.88

Est. earnings growth +0.1%

Next fiscal year

Rev $91.6B · EPS 7.39

Est. earnings growth +5.9%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2026)

$87.0B

Net margin

18.4%

ROE

29.5%

Revenue CAGR (3y)

+2.0%

Profit CAGR (3y)

+3.1%

EPS (FY2026)

6.62

Net profit (FY2026)

$16.0B

Ask MarketChacha about PG

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2026	$87.0B	$16.0B	6.62	18.4%	29.5%
FY2025	$84.3B	$16.0B	6.51	19.0%	30.6%
FY2024	$84.0B	$14.9B	6.02	17.7%	29.4%
FY2023	$82.0B	$14.7B	5.90	17.9%	31.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$21.2B	$3.9B	1.63	18.5%
2025Q4	$22.2B	$4.3B	1.78	19.4%
2025Q3	$22.4B	$4.8B	1.95	21.2%
2025Q1	$19.8B	$3.8B	1.54	19.1%
2024Q4	$21.9B	$4.6B	1.88	21.2%
2024Q3	$21.7B	$4.0B	1.61	18.2%
2024Q1	$20.2B	$3.8B	1.52	18.6%
2023Q4	$21.4B	$3.5B	1.40	16.2%
2023Q3	$21.9B	$4.5B	1.83	20.7%
2023Q1	$20.1B	$3.4B	1.37	16.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-K — FY2526 10-K
SEC8/4/2026
8-K — Reg FD disclosure, Exhibits
SEC7/29/2026material
8-K — Results of operations, Exhibits
SEC7/29/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC7/29/2026material
8-K — Reg FD disclosure, Exhibits
SEC7/14/2026material
8-K — Results of operations, Exhibits
SEC4/24/2026material
8-K — Reg FD disclosure, Exhibits
SEC4/24/2026material
10-Q — FY2526 Q3 JFM 10-Q
SEC4/24/2026
8-K — Reg FD disclosure, Exhibits
SEC4/14/2026material
10-Q — FY2526 Q2 OND 10-Q
SEC1/23/2026
8-K — Results of operations, Exhibits
SEC1/22/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/22/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/13/2026material

2025

8-K — Executive/director change
SEC12/15/2025material
8-K — Other events, Exhibits
SEC11/4/2025material
8-K — Other events, Exhibits
SEC11/3/2025material
8-K — Results of operations, Exhibits
SEC10/24/2025material
8-K — Reg FD disclosure, Exhibits
SEC10/24/2025material
10-Q — FY2526 Q1 JAS 10-Q
SEC10/24/2025
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC10/16/2025material
8-K — Reg FD disclosure, Exhibits
SEC10/14/2025material
8-K — Executive/director change
SEC8/14/2025material
10-K — FY2425 10-K
SEC8/4/2025
8-K — Results of operations, Exhibits
SEC7/29/2025material
8-K — Reg FD disclosure, Exhibits
SEC7/29/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.